Pierce Christopher 4
4 · Prelude Therapeutics Inc · Filed Apr 9, 2021
Insider Transaction Report
Form 4
Pierce Christopher
EVP and Chief of Business Oper
Transactions
- Sale
Common Stock
2021-04-07$40.08/sh−828$33,188→ 3,750 total - Award
Common Stock
2021-04-07$1.89/sh+828$1,565→ 4,578 total - Exercise/Conversion
Employee Stock Option (right to buy)
2021-04-07−828→ 7,818 totalExercise: $1.89Exp: 2030-03-26→ Common Stock (828 underlying)
Footnotes (3)
- [F1]The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F3]The stock option is fully vested.